Period:
Draw Mode:
| Volume | 136,253 |
|
|||||
| News | - | ||||||
| Day High | 1.72 | Low High |
|||||
| Day Low | 1.64 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| SELLAS Life Sciences Group Inc | SLS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.01 | -0.59% | 1.68 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.68 | 1.64 | 1.72 | 1.64 | 1.69 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 780 | 136,253 | $ 1.67 | $ 226,877 | - | 1.17 - 5.58 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:31:36 | 1 | $ 1.72 | USD |
SELLAS Life Sciences Group Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 47.62M | 28.35M | 28.30M | $ - | $ - | -0.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 587.50k | 0.80% |
SELLAS Life Sciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.69 | 1.75 | 1.64 | 1.70 | 101,970 | -0.01 | -0.59% |
| 1 Month | 1.70 | 1.80 | 1.44 | 1.66 | 148,770 | -0.02 | -1.18% |
| 3 Months | 1.37 | 1.83 | 1.17 | 1.50 | 228,356 | 0.31 | 22.63% |
| 6 Months | 2.50 | 4.13 | 1.17 | 1.91 | 313,257 | -0.82 | -32.8% |
| 1 Year | 2.97 | 5.58 | 1.17 | 2.44 | 278,826 | -1.29 | -43.43% |
| 3 Years | 3.68 | 19.38 | 1.17 | 9.84 | 689,062 | -2.00 | -54.35% |
| 5 Years | 5.29 | 19.38 | 0.1021 | 1.98 | 2,415,067 | -3.61 | -68.24% |
SELLAS Life Sciences Description
| SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax. |